Anti-tigit antibodies
AssigneeIteos Therapeutics
InventorsAnthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julie Cuende, Gregory Driessens, Florence Lambolez
Life of this patent
Estimating the term…
Abstract
Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
Claims20
An antibody or antigen binding fragment thereof which binds to human TIGIT, wherein the antibody or antigen binding fragment comprises a combination of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein:
- HCDR1 comprises SEQ ID NO:
- 16 (YTFTSYYMH),
- HCDR2 comprises SEQ ID NO:
- 17 (VIGPSGASTSYAQKFQG),
- HCDR3 comprises SEQ ID NO:
- 18 (ARDHSDYWSGIMEV),
- LCDR1 comprises SEQ ID NO:
- 61 (RASQSVRSSYLA),
- LCDR2 comprises SEQ ID NO:
- 62 (GASSRAT),
- and
- LCDR3 comprises SEQ ID NO:
- 63 (QQYFSPPWT).
A pharmaceutical composition comprising:
- i) an effective amount of an antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment binds to human TIGIT, wherein the antibody or antigen binding fragment comprises a combination of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein:
- HCDR1 comprises SEQ ID NO:
- 16 (YTFTSYYMH),
- HCDR2 comprises SEQ ID NO:
- 17 (VIGPSGASTSYAQKFQG),
- HCDR3 comprises SEQ ID NO:
- 18 (ARDHSDYWSGIMEV),
- LCDR1 comprises SEQ ID NO:
- 61 (RASQSVRSSYLA),
- LCDR2 comprises SEQ ID NO:
- 62 (GASSRAT),
- LCDR3 comprises SEQ ID NO:
- 63 (QQYFSPPWT);
- and
- ii) a pharmaceutically acceptable carrier.
A method of treating cancer according to claim 20, wherein the second therapeutic agent is selected from the group consisting of:
- a chemotherapeutic agent, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody.
Dependencies are inferred from the claim text.